A Phase III Study Evaluating the Addition of Trastuzumab to Standard Therapy for HER2-Positive Esophageal Cancers

Full Title

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma (RTOG 1010)


The standard treatment for esophageal cancer is radiation therapy and the chemotherapy drugs paclitaxel and carboplatin, followed by surgery to remove the esophagus. In this study, researchers want to see if adding the drug trastuzumab (Herceptin) to this treatment combination is more effective for reducing the risk of cancer recurrence than the standard treatment alone.

Trastuzumab works by targeting a protein called HER2, which is produced in excess in some cancers, including some esophageal cancers. In this Radiation Therapy Oncology Group study, patients will be randomly assigned to receive the standard treatment, or the standard treatment plus trastuzumab given before and after surgery. Only patients with HER2-positive esophageal cancers can receive trastuzumab.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have non-metastatic esophageal adenocarcinoma and be candidates for radiation therapy, chemotherapy, and surgery.
  • Only patients with HER2-positive cancer may receive trastuzumab.
  • Patients may not have had prior treatment for esophageal cancer.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Abraham Wu at 212-639-5257.